Investor Relations

Aptahem's vision is to deliver best in class aptamer-based drugs for sepsis and other severe inflammatory conditions, thereby saving patients’ lives and improving treatment options.

Aptahem’s business strategy is to perform active business development activities to identify future collaboration partners by frequently interact, present and discuss the company’s development status with pharmaceutical and biotechnology companies that have commercial synergies with Aptahem’s technology. The aim with these activities is to enter into a successful partnering or licence deal to generate resources to promote Aptahem’s portfolio of pharmaceutical candidates and to increase the company’s value. Aptahem’s aim is to enter into such an agreement for the drug candidate Apta-1 in early clinical phase.

Apta-1 as a new potential treatment for sepsis

Sepsis is a global, challenging and deadly health problem causing a considerable economic burden and extensive unmet clinical needs worldwide.

Up to date, there is no available cure to treat sepsis.

Aptahem’s novel drug candidate Apta-1 is an RNA aptamer that, by interacting with at least three important factors for sepsis, such as coagulation, inflammation and tissue repair, can be the sought-after solution for sepsis and other acute inflammatory conditions.

Financial Calendar

  • Apr
    26
    2023

    Annual Report 2022

  • May
    11
    2023

    Interim Report Q1 2023

  • Jun
    1
    2023

    Annual General Meeting

  • Aug
    31
    2023

    Half-year Report 2023

Events

  • Mar
    28
    2023

    BIO Europe Spring 2023 Digital

  • Mar
    30
    2023

    BioStock Executive Insights

Presentations

Interview with CEO Mikael Lindstam (in swedish)

2023-02-15